About us

Disarm Therapeutics is creating breakthrough disease-modifying therapeutics to treat patients with neurological diseases by preventing axonal degeneration.

Axonal degeneration is a common yet unaddressed pathology in a broad range of chronic and acute diseases of the central, ocular, and peripheral nervous systems.

Our scientific founders have identified SARM1 as the central driver of axonal degeneration, which causes severe sensory, motor, and cognitive symptoms and disease progression.

Disarm is developing SARM1 inhibitors to directly prevent the loss of axons, providing a breakthrough treatment approach for patients with severe neurological diseases including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies.


Disarm was founded in 2016 by Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University in St. Louis, Atlas Venture, and a team of exceptional scientists and drug developers.

Tom Engber, PhD

SVP, Head of Neuropharmacology and Translational Sciences

Scott Holmes, MS/MBA

Chief Financial Officer

Raul Krauss, PhD

Raul Krauss, PhD

Founder and VP, Head of Biology

Robert Hughes, PhD

Robert Hughes, PhD

VP, Head of Molecular Discovery

Todd Bosanac

Todd Bosanac, PhD

Senior Director, Molecular Discovery

Marco Passini, PhD

Senior Director of Pharmacology

Liza Leventhal, PhD

Director of Research Operations

Molly B. Schlagel, MS

Executive Assistant & Office Manager

Jeffrey Milbrandt, MD, PhD, co-chair

Chair, Department of Genetics, James S. McDonnell Professor of Genetics, Pathology and Immunology, Medicine, and Neurology, Washington University; founder, Disarm

Aaron DiAntonio, MD, PhD, co-chair

Alan A. and Edith L. Wolff Professor of Developmental Biology, Washington University; founder, Disarm

Peter Calabresi, MD

Professor of Neurology and Neuroscience, Director of the Multiple Sclerosis Center, and Director, Division of Neuroimmunology and Neurological Infections, Johns Hopkins University

Robert Copeland, PhD

President, CSO, and founder, Accent Therapeutics

Douglas Kerr, MD, PhD, MBA

Head of Preclinical Research and Clinical Development, Generation Bio

Gerhard Koenig, PhD

Entrepreneur in residence, Atlas Venture

Al Sandrock, MD, PhD

Executive Vice President and Chief Medical Officer, Biogen

Steven Scherer, MD, PhD

Ruth Wagner Van Meter and J. Ray Van Meter Professor of Neurology, University of Pennsylvania

Bruce Trapp, PhD

Chair Neurosciences, Cleveland Clinic